000306762 001__ 306762
000306762 005__ 20251210120038.0
000306762 0247_ $$2doi$$a10.1016/S0167-8140(25)02018-3
000306762 0247_ $$2ISSN$$a0167-8140
000306762 0247_ $$2ISSN$$a1879-0887
000306762 037__ $$aDKFZ-2025-02746
000306762 041__ $$aEnglish
000306762 082__ $$a610
000306762 1001_ $$0P:(DE-He78)87c7a90aa97629c950fb781d466f5c65$$aNiklas, Martin$$b0$$eCorresponding author
000306762 1112_ $$aThe 25th European Conference of The European Society for Radiotherapy and Oncology$$cVienna$$d2025-05-02 - 2025-05-06$$gESTRO 25$$wAustria
000306762 245__ $$a3870 Towards MRI-based biomarkers for prognostic response assessment of adaptive radiotherapy in non-small cell lung cancer (NSCLC)
000306762 260__ $$c2025
000306762 3367_ $$033$$2EndNote$$aConference Paper
000306762 3367_ $$2BibTeX$$aINPROCEEDINGS
000306762 3367_ $$2DRIVER$$aconferenceObject
000306762 3367_ $$2ORCID$$aCONFERENCE_POSTER
000306762 3367_ $$2DataCite$$aOutput Types/Conference Poster
000306762 3367_ $$0PUB:(DE-HGF)24$$2PUB:(DE-HGF)$$aPoster$$bposter$$mposter$$s1765362113_3094857$$xOther
000306762 520__ $$aTowards MRI-based biomarkers for prognostic response assessment of adaptive radiotherapy in non-small cell lung cancer (NSCLC)Introduction:Daily online adaptive radiotherapy (oART) offers superior target coverage whilst sparing organs at risk. Due to its superior soft tissue contrast, magnetic resonance imaging (MRI) might further improve oART. Moreover, MRI can additionally provide functional imaging, e.g. diffusion weighted imaging (DWI) which could allow for early tumor response assessment and functions as the basis of future dose tailoring approaches. Evidence for oART in lung cancer is scarce and to the best of our knowledge non-existent for the combination with offline diagnostic MR-guidance.Methods:From June 2023 to February 2024, 13 patients with locally advanced NSCLC underwent chemoradiotherapy (CRT) at the ETHOS linear accelerator (Varian Medical Systems) for daily oART. All patients received weekly 3T MRI (T1, T2, DWI) in treatment position using a shuttle (CQ Medical Limited), which is utilized for plan adaptation (i.e. offline diagnostic MR-guidance). Target volumes were segmented in the daily cone beam computed tomography aided by the weekly co-registered MRI sequences. Results:The 3dim volume change of the NSCLC could be quantified by different MRI sequences (Figure 1). First results showed an increase in the calculated mean apparent diffusion coefficient (ADC) in the 3dim tumor volume of NSCLC in parallel to a volume shrinkage characterized by T2 imaging, which could be interpreted as successful response to CRT by the adaptive ETHOS workflow. The ADC map could thus be a potential morphological and functional biomarker for prognostic response assessment next to dynamic contrast-enhanced MRI. Still, due to artifacts, arising from respiratory and cardiac movements as well as differences in the susceptibility of neighboring organs, the target volume might not be defined by the DWI MRI alone. It could yet serve for strategy adaptation in oART. Sub-regions of very low ADC values (corresponding to high cell density) in the heterogenous ADC map of the tumor volume were observed and could act as potential target volumes in boost strategies in oART. Conclusion:This ongoing study will address the characterization of NSCLC by offline 3T MRI. It will also address the value of thoracic DWI for defining morphological and functional biomarkers for possible boost strategies in oART, early risk stratification and for prognosis assessment of NSCLC.
000306762 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000306762 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000306762 7001_ $$0P:(DE-He78)7b7d3650efd9aeb0aff30e7fbed3ecac$$aGiske, Kristina$$b1$$udkfz
000306762 7001_ $$0P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aGnirs, Regula$$b2$$udkfz
000306762 7001_ $$0P:(DE-He78)82090937e7b88ac8ec70bbc40ad6b512$$aSedlaczek, Oliver$$b3$$udkfz
000306762 7001_ $$0P:(DE-He78)af2fba3014dac56ccf4188c9879dce19$$aJende, Johann$$b4$$udkfz
000306762 7001_ $$0P:(DE-He78)a56941777fbaf0ca1008366e7e16667f$$aZiener, Christian$$b5$$udkfz
000306762 7001_ $$0P:(DE-HGF)0$$aSaßmannshausen, Philipp Hoegen$$b6
000306762 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b7$$udkfz
000306762 7001_ $$aRegnery, Sebastian$$b8
000306762 7001_ $$aHörner-Rieber, Juliane$$b9
000306762 7001_ $$0P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aJäkel, Oliver$$b10$$udkfz
000306762 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b11$$udkfz
000306762 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b12$$udkfz
000306762 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b13$$udkfz
000306762 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/S0167-8140(25)02018-3$$gVol. 206, p. S1415 - S1416$$x0167-8140$$y2025
000306762 8564_ $$uhttps://inrepo02.dkfz.de/record/306762/files/Abstract_Estro_MNS.docx$$yRestricted
000306762 909CO $$ooai:inrepo02.dkfz.de:306762$$pVDB
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)87c7a90aa97629c950fb781d466f5c65$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7b7d3650efd9aeb0aff30e7fbed3ecac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)82090937e7b88ac8ec70bbc40ad6b512$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)af2fba3014dac56ccf4188c9879dce19$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a56941777fbaf0ca1008366e7e16667f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440a3f62ea9ea5c63375308976fc4c44$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000306762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000306762 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000306762 9141_ $$y2025
000306762 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-07$$wger
000306762 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2022$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000306762 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bRADIOTHER ONCOL : 2022$$d2025-01-07
000306762 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000306762 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x1
000306762 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x2
000306762 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x3
000306762 980__ $$aposter
000306762 980__ $$aVDB
000306762 980__ $$aI:(DE-He78)E010-20160331
000306762 980__ $$aI:(DE-He78)E040-20160331
000306762 980__ $$aI:(DE-He78)E055-20160331
000306762 980__ $$aI:(DE-He78)E050-20160331
000306762 980__ $$aUNRESTRICTED